Understanding the contributions of VPS35 and the retromer in neurodegenerative disease

• Published in: Neurobiology of disease 2022-08, Vol.170, p.105768-105768, Article 105768
• Main Authors: Williams, Erin T., Chen, Xi, Otero, P. Anthony, Moore, Darren J.
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Amyotrophic lateral sclerosis; Autophagy; Cargo; Endosome; Golgi; LRRK2; Lysosome; Mitochondria; Parkinson's disease; Retromer complex; Tau; Tauopathies; Vesicular sorting; VPS35
• ISSN: 0969-9961; 1095-953X
• DOI: 10.1016/j.nbd.2022.105768

Perturbations of the endolysosomal pathway have been suggested to play an important role in the pathogenesis of several neurodegenerative diseases, including Parkinson's disease (PD) and Alzheimer's disease (AD). Specifically, VPS35 and the retromer complex play an important role in the endolysosomal system and are implicated in the pathophysiology of these diseases. A single missense mutation in VPS35, Asp620Asn (D620N), is known to cause late-onset, autosomal dominant familial PD. In this review, we focus on the emerging role of the PD-linked D620N mutation in causing retromer dysfunction and dissect its implications in neurodegeneration. Additionally, we will discuss how VPS35 and the retromer are linked to AD, amyotrophic lateral sclerosis, and primary tauopathies. Interestingly, reduced levels of VPS35 and other retromer components have been observed in post-mortem brain tissue, suggesting a role for the retromer in the pathophysiology of these diseases. This review will provide a comprehensive dive into the mechanisms of VPS35 dysfunction in neurodegenerative diseases. Furthermore, we will highlight outstanding questions in the field and the retromer as a therapeutic target for neurodegenerative disease at large.